Pharmaceutical Processors-CBD/THC-A Oil
Updates and General Overview regarding Allowances for CBD/THC-A Oil. Read more.
SB1557 authorizes physician assistants and nurse practitioners to issue written certifications to patients beginning July 1, 2019.
CBD Oil and THC-A Oil Registration Applications for Patients, Parents/Legal Guardians, Registered Agents and Practitioners Now Available
The law provides for an affirmative defense for a patient, parent or legal guardian to possess cannabidiol (CBD) oil or THC-A oil, as defined in §54.1-3408.3 of the Code of Virginia who has been issued a valid written certification from a Board of Pharmacy-registered practitioner and who maintains a current registration with the Board of Pharmacy.
Before a practitioner can issue or continue issuing written certifications, he or she must register with the Board of Pharmacy. Learn More about Practitioner Registration.
A patient, parent or legal guardian must have a written certification issued to them by a registered practitioner prior to applying for registration with the Board of Pharmacy and possessing the oils. Learn More about Patient/Parent/Guardian Registration.
A patient, or the patient’s parent or legal guardian, may chose a registered agent to receive cannabidiol oil or THC-A oil on behalf of the patient. . Learn More about Registered Agent Registration.
A pharmaceutical processor is a facility that has obtained a permit from the Board of Pharmacy pursuant to §54.1-3408.3 to cultivate Cannabis plants for the production of cannabidiol oil or THC-A oil, and dispense the oil to patients registered by the Board of Pharmacy for treatment or to alleviate the symptoms of any diagnosed condition or disease determined by the physician to benefit from such use. As set forth in §54.1-3442.6 of the Code of Virginia, the Board may issue or renew a maximum of 5 permits, one for each health service area established by the Board of Health. The Board issued conditional approval to five applicants in 2018. It is anticipated that CBD/THC-A oil products will be available from the pharmaceutical processors in Summer 2020, following construction and board inspection.